



## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, O.C. 20231

SERIAL NUMBER	FILING DATE		FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
0 22 2 32 9 880	05771973B	farrés.	T <sub>x</sub>	\$12:20022F25

APTOMELLE (LIKK) & MARKS (202 PA: AVE.) d. W., SIC. BOB MACHINGTON, DC 1888.

EXAMINER				
14 A 148 11 19 19 4				
ART UNIT	PAPER NUMBER			
J. J. 35	-46			
DATE MAILED: 13	W 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2			

This is a communication from the examiner in charge of your application.

## COMMISSIONER OF PATENTS AND TRADEMARKS

-	
This application has been examined $\frac{1}{3/86}$	This action is made final.
A shortened statutery excited for second to the second to	
A shortened statutory period for response to this action is set to expire month(s), days from failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C.	m the date of this letter.
25 U.S.C	133
Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:	
1. Notice of References Cited by Examiner, PTO-892.	ng, PTO-948.
	ent Application, Form PTO-152
5. Information on How to Effect Drawing Changes, PTO-1474 6.	
Part II SUMMARY OF ACTION	
1-5 7-20	
1. Claims / -5 / -20	are pending in the application.
<b>A.</b> W	
Of the above, claims	are withdrawn from consideration.
2. Claims	have been cancelled.
3. St Claims 1-5, 7-15	are allowed
4. (Claims / 6 - 20	are rejected.
5. Claims	are objected to.
6. Claims are subject to	restriction or election requirement.
7. [ ] This application has been filed with informal drawings which are acceptable for examination purpos matter is indicated.	es until such time as allowable subject
Allowable subject matter having been indicated, formal drawings are required in response to this Of	fice action.
9. The corrected or substitute drawings have been received on These draw	wings are [_] acceptable;
not acceptable (see explanation).	
10. [_] The[_] proposed drawing correction and/or the [_] proposed additional or substitute sheet(s) of dr	awings filed on
has (have) been [ ] approved by the examiner. [ ] disapproved by the examiner (see explanation)	
11. The proposed drawing correction, filed, has been approved. d	isapproved (see explanation). However,
the Patent and Trademark Office no longer makes drawing changes. It is now applicant's responsib	
corrected. Corrections <u>MUST</u> be effected in accordance with the instructions set forth on the attac EFFECT ORAWING CHANGES", PTO-1474.	med letter "INFORMATION ON HOW TO
, , , , , , , , , , , , , , , , , , , ,	
12. Acknowledgment is made of the claim for priority under 35 U.S.C. 119. The certified copy has	been received not been received
been filed in parent application, serial no; filed on;	
13. Since this application appears to be in condition for allowance except for formal matters, prosecution accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.	
14. Other	

EXAMINER'S ACTION

Serial No. 737,880

Art Unit 116

Claims 16-20 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over the prior invention as set forth in claim 14 of U.S. patent no. 4,576,928. Although the conflicting claims are not identical, they are not patentably distinct from each other because nothing unobvious is seen in the limitations in the present claims. The sulfated compound in present claims 16-18 and the dextran sulfate of present claims 19 and 20 are species of the ligand in claim 14 of the patent.

The obviousness-type double patenting rejection is a judicially established doctrine based upon public policy and is primarily intended to prevent prolongation of monopoly by prohibiting claims in a second patent not patentably distinct from claims in a first patent. In re Vogel, 164 USPQ 619 (CCPA 1970). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(b) would overcome an actual or provisional rejection on this ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.78(d).

Claims 16-19 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over the prior invention as set forth in claim 15 of U.S. patent no. 4,576,928. Although the conflicting claims are not identical, they are not patentably distinct from each other because nothing unobvious is seen in the limitations in the present claims.

The obviousness-type double patenting rejection is a judicially established doctrine based upon public policy and is primarily intended to prevent prolongation of monopoly by prohibiting claims in a second patent not patentably distinct from claims in a first patent. In re Vogel, 164 USPQ 619 (CCPA 1970). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(b) would overcome an actual or provisional rejection on this ground provided the conflicting

Serial No. 737,880

Art Unit 116

application or patent is shown to be commonly owned with this application. See 37 CFR 1.78(d).

Claim 20 is rejected under 35 U.S.C. 101 as claiming the same invention as that of claim 15 of prior U.S. Patent No. 4,576,928. The cellutose gel of present claim 20 and the other limitations in the claim are the same limitations in applicants' patent claim. This is a double patenting rejection.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). The practice of automatically extending the shortened statutory period an additional month upon the filing of a timely first response to a final rejection has been discontinued by the Office. See 1021 TMOG 35.

A SHORTENED STATUTORY PERIOD FOR RESPONSE TO THIS FINAL ACTION IS SET TO EXPIRE THREE MONTHS FROM THE DATE OF THIS ACTION. IN THE EVENT A FIRST RESPONSE IS FILED WITHIN TWO MONTHS OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION IS NOT MAILED UNTIL AFTER THE END OF THE THREE-MONTH SHORTENED STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE PURSUANT TO 37 CFR 1.136(a) WILL BE CALCULATED FROM THE MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE STATUTORY PERIOD FOR RESPONSE EXPIRE LATER THAN SIX MONTHS FROM THE DATE OF THIS FINAL ACTION.

WShine:mr

703-557-2621

3/24/86

W. SHINE
PRIMARY PATENT EXAMINER
ART UNIT 116